An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

If you’re living with ulcerative colitis (UC), managing flares is often a key part of your care plan. While lifestyle changes and other first-line treatments may help manage inflammation, many people ...

Patients with active ulcerative colitis may be able to reduce symptoms and achieve remission by taking a plant-based treatment combining the herbal compounds curcumin and qingdai, preliminary results ...

We don’t know exactly what causes ulcerative colitis (UC). We do know it happens because of a faulty response by your immune system. Your body may mistake food and normal gut bacteria as harmful ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ulcerative Colitis pipeline constitutes 70+ key companies continuously working towards developing 75+ ...

Mirikizumab treatment is safe and efficacious for ulcerative colitis up to 152 weeks in those with and without previous biologic therapy failure. Mirikizumab treatment for 152 weeks is associated with ...

You and your doctor already have a variety of treatment options available for ulcerative colitis (UC), but science marches on, with the pharmaceutical industry close behind. Dozens of novel therapies ...

News and commentary from the world of gastroenterology and hepatology ...

A new drug, investigated by Amsterdam UMC together with colleagues around the world, is effective as a treatment against ulcerative colitis. With the clinical trial demonstrating a doubling in the ...

Managing inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, may soon become more advanced and ...

Using an early patient experience as a launching point, Miguel Regueiro, MD, reflects on the gradual shift away from treatments for ulcerative colitis, such as the long-term prescribing of steroids ...